Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
Ramalingam, Suresh S, Vansteenkiste, Johan, Planchard, David, Cho, Byoung Chul, Gray, Jhanelle E, Ohe, Yuichiro, Zhou, Caicun, Reungwetwattana, Thanyanan, Cheng, Ying, Chewaskulyong, Busyamas, Shah, Riyaz, Cobo, Manuel, Lee, Ki Hyeong, Cheema, Parneet, Tiseo, Marcello, John, Thomas, Lin, Meng-Chih, Imamura, Fumio, Kurata, Takayasu, Todd, Alexander, Hodge, Rachel, Saggese, Matilde, Rukazenkov, Yuri, Soria, Jean-Charles, FLAURA Investigators
2020Open MIND287 citations
Topics & Concepts
OsimertinibMedicineOverall survivalInternal medicineOncologySurvival analysisSurvival rateMEDLINEProgression-free survivalClinical trialLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways